Immune Checkpoint Inhibitor-Associated Pericarditis.

Autor:	Altan M; Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: maltan@mdanderson.org., Toki MI; Department of Pathology, Yale School of Medicine, New Haven, Connecticut., Gettinger SN; Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut., Carvajal-Hausdorf DE; Department of Pathology, Yale School of Medicine, New Haven, Connecticut; Anatomic Pathology, Clinica Alemana-Facultad de Medicina Universidad de Desarrollo, Vitacura, Santiago, Chile., Zugazagoitia J; Department of Pathology, Yale School of Medicine, New Haven, Connecticut., Sinard JH; Department of Pathology, Yale School of Medicine, New Haven, Connecticut., Herbst RS; Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut., Rimm DL; Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut; Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Jun; Vol. 14 (6), pp. 1102-1108. Date of Electronic Publication: 2019 Mar 07.
DOI:	10.1016/j.jtho.2019.02.026
Abstrakt:	Side effects of immune checkpoint inhibitors, termed immune-related adverse events, are relatively common, but immune checkpoint inhibitor-mediated cardiotoxicities are rare; however, they can be serious and potentially fatal. Pericarditis is an infrequent cardiac toxicity of immunotherapy and predisposing factors remain unknown. Here we report three patients with NSCLC who developed pericarditis during therapy with programmed death 1/programmed death ligand 1+/- CTLA-4 inhibitors. We review the clinical presentation of these three cases and histopathologic findings from autopsies from the first two patients and a pericardial sampling that has been obtained from a pericardial window procedure in the third patient who recovered from the pericarditis episode. We also discuss the potential mechanisms, as well as what is known about pericarditis secondary to immune-related adverse events. (Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu